Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Vinorelbine Tartrate

FDA-approved product (injectable, injection), marketed as Navelbine, Vinorelbine Tartrate.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Vinorelbine Tartrate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cancer
  • Neoplasm

Indications ChEMBL records as approved, from FDA and DailyMed labels.

WHO therapeutic group
Vinca alkaloids and analogues
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA, E. coli and K. pneumoniae. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA63.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli50.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae40.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis64.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Vinorelbine Tartrate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Vinorelbine Tartrate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Cisplatin Plus Vinorelbine With or Without Tirapazamine in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

    NCT00017459 · start 2000-07

    Registered record
    Registry ID
    NCT00017459
    Conditions
    Lung Cancer
    Interventions
    cisplatin; tirapazamine; vinorelbine tartrate
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2000-07
    Completion
    2004-02
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLung Cancer
    Interventioncisplatin; tirapazamine; vinorelbine tartrate
    PhasePhase 3
    Registry statusCompleted

  • Combination Chemotherapy Plus Radiation Therapy With or Without AE-941 in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed By Surgery

    NCT00005838 · start 2000-03

    Registered record
    Registry ID
    NCT00005838
    Conditions
    Adenocarcinoma of the Lung; Adenosquamous Cell Lung Cancer; Large Cell Lung Cancer; Squamous Cell Lung Cancer; Stage IIIA Non-small Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer
    Interventions
    shark cartilage extract AE-941; placebo; cisplatin; vinorelbine tartrate; carboplatin; paclitaxel; radiation therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2000-03
    Completion
    Not recorded
    Enrolment
    756

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdenocarcinoma of the Lung; Adenosquamous Cell Lung Cancer; Large Cell Lung Cancer; Squamous Cell Lung Cancer +2 more
    Interventionshark cartilage extract AE-941; placebo; cisplatin; vinorelbine tartrate +3 more
    PhasePhase 3
    Registry statusCompleted

  • Chemotherapy Plus Trastuzumab in Treating Patients With Breast Cancer

    NCT00014430 · start 1999-11

    Registered record
    Registry ID
    NCT00014430
    Conditions
    Breast Cancer
    Interventions
    trastuzumab; vinorelbine ditartrate
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    1999-11
    Completion
    Not recorded
    Enrolment
    13

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer
    Interventiontrastuzumab; vinorelbine ditartrate
    PhasePhase 1
    Registry statusCompleted

  • Capecitabine and Vinorelbine in Treating Older Women Who Have Metastatic Breast Cancer With or Without Bone Involvement

    NCT00003902 · start 1999-03

    Registered record
    Registry ID
    NCT00003902
    Conditions
    Breast Cancer
    Interventions
    capecitabine; vinorelbine tartrate
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    1999-03
    Completion
    2005-09
    Enrolment
    110

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer
    Interventioncapecitabine; vinorelbine tartrate
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Comparison of Three Combination Chemotherapy Regimens in Treating Women With Stage I or Stage II Breast Cancer

    NCT00004237 · start 1998-10

    Registered record
    Registry ID
    NCT00004237
    Conditions
    Breast Cancer
    Interventions
    cyclophosphamide; doxorubicin hydrochloride; epirubicin hydrochloride; mitoxantrone hydrochloride; vinorelbine tartrate; conventional surgery; radiation therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    1998-10
    Completion
    2005-09
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer
    Interventioncyclophosphamide; doxorubicin hydrochloride; epirubicin hydrochloride; mitoxantrone hydrochloride +3 more
    PhasePhase 2
    Registry statusCompleted